| 25 Apr 2025 | GRC 65327 | Discovery of GRC 65327: A Novel, Selective and Potent CBL-B E3 Ligase Inhibitor for the Treatment of Advanced Solid Cancers | Udupa V. et al. | American Association for Cancer Research Annual Meeting |  |
| 25 Apr 2025 | ISB 2001 | Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed/refractory multiple myeloma (RRMM) patients | Menon V. et al. | American Association for Cancer Research Annual Meeting | |
| 25 Apr 2025 | ISB 2001 | Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the First-in-Human (FIH) Phase 1 study in relapsed/refractory multiple myeloma patients | Garton A. et al. | American Association for Cancer Research Annual Meeting | |
| 30 Jan 2025 | ISB 1442 | Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity | Loyau J. et al.
| mAbs | |
| 09 Dec 2024 | ISB 2001 | First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) | Quach H. et al.
| American Society of Hematology Annual Meeting | |
| 08 Dec 2024 | ISB 1442 | Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma | Dhakal, B. et al.
| American Society of Hematology Annual Meeting | |
| 09 Nov 2024 | GRC 65327 | Poster: GRC 65327, a novel small molecule selective Cbl-b inhibitor for solid tumors | Chaudhari, S. et al.
| Society for Immunotherapy of Cancer | |
| 11 Sep 2024 | ISB 2001 | ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells | Carretero-Iglesia L. et al.
| Nature Cancer | |
| 20 Jun 2024 | BEAT® Antibody Engineering Platform | Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach | Peltret M. et al. | Journal of Biotechnology
| |
| 22 Apr 2024 | BEAT® Antibody Engineering Platform | Alternative splicing for tuneable expression of protein subunits at desired ratios
| Aebischer-Gumy C. et al.
| mAbs | |
| 07 Apr 2024 | ISB 2001 | Oral Presentation: ISB 2001, a BCMA and CD38 dual targeting T-cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patients relapsing from CD38 and BCMA targeted immunotherapies
| Carretero-Iglesia L. et al. | American Association for Cancer Research Annual Meeting | |
| 06 Mar 2024 | ISB 1442 | Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
| Grandclément C. et al.
| Nature Communications
| |
| 11 Dec 2023 | ISB 1442 | Poster: Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
| Kazandjian D. et al. | American Society of Hematology Annual Meeting | |
| 10 Dec 2023 | ISB 1342 | Poster: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
| Kapoor P. et al. | American Society of Hematology Annual Meeting | |
| 10 Dec 2023 | ISB 2001 | Poster: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma (RRMM) | Sia H. et al. | American Society of Hematology Annual Meeting | |
| 05 Nov 2023 | GRC 54276 | Clinical Abstract: Phase 1 First In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Grc 54276, A Novel HPK1 Thronine-Kinase Inhibitor, In Advanced Solid Tumours And Lymphomas. | Doddihal H. et. al. | European Hematology Association | |
| 22 May 2023 | ISB 1342 | Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple Myeloma | Perro M. et al. | Blood | |
| 17 Apr 2023 | ISB 2001 | Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell Engager | Perro M. et al. | American Association for Cancer Research Annual Meeting | |
| 12 Dec 2022 | ISB 1442 | Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma | Jiang T. et al. | American Society of Hematology Annual Meeting | |
| 12 Dec 2022 | ISB 1442 | Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma | Jiang T. et al. | American Society of Hematology Annual Meeting | |
| 11 Dec 2022 | ISB 1342 | Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) | Mohan S. et al. | American Society of Hematology Annual Meeting | |
| 11 Dec 2022 | ISB 1342 | Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) | Mohan S. et al. | American Society of Hematology Annual Meeting | |
| 11 Dec 2022 | ISB 1442 | Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL | Sammicheli S. et al. | American Society of Hematology Annual Meeting | |
| 11 Dec 2022 | ISB 1442 | Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL | Sammicheli S. et al. | Presentation at the American Society of Hematology Annual Meeting | |
| 10 Dec 2022 | ISB 2001 | ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two Antigens | Perro M. et al. | Presentation at the American Society of Hematology Annual Meeting | |
| 28 Jun 2022 | Process Development | Optimization of a Cell Culture Clarification Platform Process With the Aim of Boosting the Recovery of Bispecific Antibodies | Mette R. et al. | ESACT2022 Conference | |
| 28 Jun 2022 | Process Development | Increased Throughput in Upstream Development via Automated Feed Strategy Using Qubicon® | Schmid S. et al. | ESACT2022 Conference | |
| 27 Jun 2022 | Process Development | Assessment Of The Impact Of The Milling Type And Production Site For Cell Culture Feed Production | Le Moal M. et al. | ESACT2022 Conference | |
| 10 Jun 2022 | ISB 1442 | ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies | Sammicheli S. et al. | EHA2022 | |
| 13 Apr 2022 | ISB 1442 | ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies | Sammicheli S. et al. | American Association for Cancer Research Annual Meeting | |
| 10 Dec 2021 | ISB 1442 | Oral Presentation: Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma | Sammicheli S. et al. | American Society of Hematology Annual Meeting | |
| 10 Dec 2021 | ISB 1442 | Oral Presentation: ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma | Sammicheli S. et al. | Blood | |
| 04 Jun 2021 | ISB 1342 | Poster:ISB 1342, A First-In-Class CD38 T Cell Engager for the Treatment of Relapsed Refractory Multiple Myeloma | Doucey, M. | American Society of Clinical Oncology Annual Meeting | |
| 03 May 2021 | ISB 830 | Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 Weeks | Sher, L. | 2021 Society for Investigative Dermatology Virtual Meeting | |
| 28 Jan 2021 | Cell Line Development | Generation of homogeneous cell populations with tunable levels of transgene expression | Schlicht D. et al. | Journal of Biotechnology | |
| 13 May 2020 | BEAT® Antibody Engineering Platform | A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species | Stutz C. et al. | Journal of Biological Chemistry | |
| 12 Sep 2019 | BEAT® Antibody Engineering Platform | Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development | Ollier R. et al. | mAbs | |
| 06 Feb 2019 | ISB 830 | GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis | Guttman-Yassky E. et al. | Journal of Allergy and Clinical Immunology | |
| 27 Apr 2017 | BEAT® Antibody Engineering Platform | Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies | Skegro D. et al. | Journal of Biological Chemistry | |
